US5153003A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Composition for forming antithrombotic medical appliances
Assignee: Sankyo Co Ltd
•
Filing: 1989-10-18
•
Granted: 1992-10-06
•
Expires: 2009-10-18
Abstract
Abstract A composition comprising a polymer having dispersed therethrough a prostacyclin derivative selected from the group consisting of compounds of formula (I): ##STR1## (in which R 1 represents hydrogen or lower alkyl, R 2 represents a C 3 -C 12 alkyl group or a C 3 -C 12 alkenyl group; and n is an integer from 1 to 5; and pharmaceutically acceptable salts thereof) can be used to make a medical appliance from which the prostaglandin, having antithrombotic properties, will be released gradually and in a controlled way.
Inventors
- 👤 Kozo Kurihara
- 👤 Hironobu Saito
- 👤 Yukie Misho
- 👤 Takeshi Oshima
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-23 19:38
CPC Classifications
A; A61; A61L; A61L33/00; A61L33/0005; A61L33/0011; A61L33/0041
Claims Analysis
Total Claims: 15
Claim 1
Independent Claim
100 words
A medical appliance wherein at least a surface portion thereof is composed of an antithrombotic composition comprising a medically acceptable polymer having distributed therethrough an antithrombotic effective amount of a prostacyclin or mixture prostacyclins selected from the group consisting of compounds of formula (I): ##STR3## in which: R 1 represents a hydrogen atom or a C 1 -C 6 alkyl group; R 2 represents a C 3 -C 12 alkyl group or a C 3 -C 12 alkenyl group; and n is an integer of from 1 to 5; and pharmaceutically acceptable salts thereof, and wherein said polymer is silicone.
Claim 2
Dependent Claim
100 words
A medical appliance wherein at least a surface portion thereof is composed of an antithrombotic composition comprising a medically acceptable polymer having distributed therethrough an antithrombotic effective amount of a prostacyclin or mixture prostacyclins selected from the group consisting of compounds of formula (I): ##STR3## in which: R 1 represents a hydrogen atom or a C 1 -C 6 alkyl group; R 2 represents a C 3 -C 12 alkyl group or a C 3 -C 12 alkenyl group; and n is an integer of from 1 to 5; and pharmaceutically acceptable salts thereof, and wherein said polymer is silicone.
Claim 3
Dependent Claim
42 words
A medical appliance as claimed in claim 1, wherein: R 1 represents a hydrogen atom or a C 1 -C 5 alkyl group; and R 2 represents a C 4 -C 10 alkyl group or a C 5 -C 12 alkenyl group.
Claim 4
Dependent Claim
42 words
A medical appliance as claimed in claim 1, wherein: R 1 represents a hydrogen atom or a C 1 -C 3 alkyl group; and R 2 represents a C 4 -C 10 alkyl group or a C 5 -C 12 alkenyl group.
Claim 5
Dependent Claim
12 words
A medical appliance as claimed in claim 1, wherein n is 3.
Claim 6
Dependent Claim
23 words
A medical appliance as claimed in claim 1, wherein said prostacyclin is selected from the group consisting of: 6,9-methylene-11,15-dihydroxyprost-5,13-dienoic acid; 6,9-methylene-11,15-dihydroxy-17-methylprost-5,13-dienoic acid; 6.
Claim 7
Dependent Claim
7 words
9-methylene-11,15-dihydroxy-16,16-dimethylprost-5,13-dienoic acid; 6,9-methylene-11,15-dihydroxy-20-isopropylideneprost-5,13-dienoic acid; 6,9-methylene-11,15-dihydroxy-17-methyl-20-isopropylideneprost-5,13-dienoic acid; and
Claim 8
Dependent Claim
7 words
9-methylene-11,15-dihydroxy-16,16-dimethylprost-5,13-dienoic acid; 6,9-methylene-11,15-dihydroxy-20-isopropylideneprost-5,13-dienoic acid; 6,9-methylene-11,15-dihydroxy-17-methyl-20-isopropylideneprost-5,13-dienoic acid; and
Claim 9
Dependent Claim
38 words
and pharmaceutically acceptable salts thereof. 6. A medical appliance as claimed in claim 1, wherein said prostacyclin is selected from the group consisting of: 6,9α-methylene-11α,15α-dihydroxyprost-5(Z),13(E)-dienoic acid; 6,9α-methylene-11α,15β-dihydroxyprost-5(Z),13(E)-dienoic acid; 6,9α-methylene-11α,15α-dihydroxyprost-5(E),13(E)-dienoic acid; 6,9α-methylene-11α,15β-dihydroxyprost-5(E),13(E)-dienoic acid; 6,9α-methylene-11α,15α-dihydroxy-17-methylprost-5(Z),13(E)-dienoic acid; 6,9α-methylene-11α,15β-dihydroxy-17-methylprost-5(Z),13(E)-dienoic acid; 6,9α-methylene-11α,15α-dihydroxy-17-methylprost-5(E),13(E)-dienoic acid;
Claim 10
Dependent Claim
25 words
9α-methylene-11α,15β-dihydroxy-17-methylprost-5(E),13(E)-dienoic acid; 6,9α-methylene-11α,15α-dihydroxy-16,16-dimethylprost-5(Z),13(E)-dienoic acid; 6,9α-methylene-11α,15β-dihydroxy-16,16-dimethylprost-5(Z),13(E)-dienoic acid; 6,9α-methylene-11α,15α-dihydroxy-16,16-dimethylprost-5(E),13(E)-dienoic acid; 6,9α-methylene-11α,15β-dihydroxy-16,16-dimethylprost-5(E),13(E)-dienoic acid; 6,9α-methylene-11α,15α-dihydroxy-20-isopropylideneprost-5(Z),13(E)-dienoic acid; 6,9α-methylene-11α,15β-dihydroxy-20-isopropylideneprost-5(Z),13(E)-dienoic acid; 6,9α-methylene-11α,15α-dihydroxy-20-isopropylideneprost-5(E),13(E)-dienoic acid; 6,9α-methylene-11α,15β-dihydroxy-20-isopropylideneprost-5(E),13(E)-dienoic acid; 6,9α-methylene-11α,15α-dihydroxy-17-methyl-20-isopropylideneprost-5(Z),13(E)-dienoic acid; 6,9α-methylene-11α,15β-dihydroxy-17-methyl-20-isopropylideneprost-5(Z),13(E)-dienoic acid; 6,9α-methylene-11α,15α-dihydroxy-17-methyl-20-isopropylideneprost-5(E),13(E)-dienoic acid and;
Claim 11
Dependent Claim
25 words
9α-methylene-11α,15β-dihydroxy-17-methylprost-5(E),13(E)-dienoic acid; 6,9α-methylene-11α,15α-dihydroxy-16,16-dimethylprost-5(Z),13(E)-dienoic acid; 6,9α-methylene-11α,15β-dihydroxy-16,16-dimethylprost-5(Z),13(E)-dienoic acid; 6,9α-methylene-11α,15α-dihydroxy-16,16-dimethylprost-5(E),13(E)-dienoic acid; 6,9α-methylene-11α,15β-dihydroxy-16,16-dimethylprost-5(E),13(E)-dienoic acid; 6,9α-methylene-11α,15α-dihydroxy-20-isopropylideneprost-5(Z),13(E)-dienoic acid; 6,9α-methylene-11α,15β-dihydroxy-20-isopropylideneprost-5(Z),13(E)-dienoic acid; 6,9α-methylene-11α,15α-dihydroxy-20-isopropylideneprost-5(E),13(E)-dienoic acid; 6,9α-methylene-11α,15β-dihydroxy-20-isopropylideneprost-5(E),13(E)-dienoic acid; 6,9α-methylene-11α,15α-dihydroxy-17-methyl-20-isopropylideneprost-5(Z),13(E)-dienoic acid; 6,9α-methylene-11α,15β-dihydroxy-17-methyl-20-isopropylideneprost-5(Z),13(E)-dienoic acid; 6,9α-methylene-11α,15α-dihydroxy-17-methyl-20-isopropylideneprost-5(E),13(E)-dienoic acid and;
Claim 12
Dependent Claim
7 words
9α-methylene-11α,15β-dihydroxy-17-methyl-20-isopropylideneprost-5(E),13(E)-dienoic acid; and pharmaceutically acceptable salts thereof.
Claim 13
Dependent Claim
7 words
9α-methylene-11α,15β-dihydroxy-17-methyl-20-isopropylideneprost-5(E),13(E)-dienoic acid; and pharmaceutically acceptable salts thereof.
Claim 14
Dependent Claim
12 words
A medical appliance as claimed in claim 1, which is a catheter.
Claim 15
Dependent Claim
12 words
A medical appliance as claimed in claim 6, which is a catheter.
References Cited (Backward Citations)
US3860701A
Cited
US3645955A
Cited
US3932656A
Cited
US3767695A
Cited
US3826678A
Cited
DE2821737A1
Cited
GB2012265A
Cited
US4433072A
Cited
US4425358A
Cited
JPS5810539A
Cited
US4360685A
Cited
US4604412A
Cited
EP0136916A2
Cited
US4563485A
Cited
US4713402A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1995-10-06 | 1996-04-06 | 1996-10-06 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1999-10-06 | 2000-04-06 | 2000-10-06 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2003-10-06 | 2004-04-06 | 2004-10-06 | $7700.00 | Window Closed / Lapsed |